Edema, Congestive heart failure, hepatic disease, Renal disease, Nephrotic syndrome
Bumetanide is a loop diuretic with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg Bumetanide has a diuretic potency equivalent to approximately 40 mg furosemide. The major site of Bumetanide action is the ascending limb of the loop of Henle.
Bumetanide inhibits sodium reabsorption in the ascending limb of the loop of Henle. Reabsorption of chloride in the ascending limb is also blocked by Bumetanide.
Bumetanide may have an additional action in the proximal tubule. Since phosphate reabsorption takes place largely in the proximal tubule, phosphaturia during Bumetanide induced diuresis is indicative of this additional action. This proximal tubular activity does not seem to be related to an inhibition of carbonic anhydrase. Bumetanide does not appear to have a noticeable action on the distal tubule.
Oedema BY MOUTH Adult: 1 mg, dose to be taken in the morning, then 1 mg after 6-8 hours if required Elderly: 500 micrograms daily, this lower dose may be sufficient in elderly patients Oedema, severe cases BY MOUTH Adult: Initially 5 mg daily, increased in steps of 5 mg every 12-24 hours, adjusted according to response.
Lithium: Lithium should generally not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
Probenecid: should not be administered concurrently with Bumetanide.
Indomethacin: Concurrent therapy with Bumetanide is not recommended.
Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.
Anticoagulants: Interaction studies in humans have shown Bumetanide to have no effect on warfarin metabolism.
Breast pain . gynaecomastia . musculoskeletal pain (associated with high doses in renal failure).
PREGNANCY Bumetanide should not be used to treat gestational hypertension because of the maternal hypovolaemia associated with this condition. BREAST FEEDING No information available. May inhibit lactation.
Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)